Please assess the completion status of the following clinical trial:

Trial Title: Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Both man and woman who is over 19years old.~* Hypertension with primary cholesterolemia and satisfy the lab results that Mean msSBP is under 180mmHg and Mean msDBP is under 110mmHg and LDL-C is 250mg/DL or under and Triglycerides is under 400mg/dL~Exclusion Criteria:~* Therapeutic lifestylechange is not enought during the study period~* SBP difference is bigger than 20mmHg or DBP difference is bigger than 10mmHg at screening visit

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CR group (Type: EXPERIMENTAL): DP-R208+Candesartan 32mg pla+Rosuvastatin 20mg pla
- CP group (Type: ACTIVE_COMPARATOR): DP-R208 pla+Candesartan 32mg+Rosuvastatin 20mg pla
- PR group (Type: ACTIVE_COMPARATOR): DP-R208 pla+Candesartan 32mg pla+Rosuvastatin 20mg

Based on this trial design, predict the completion outcome and termination type (if applicable).